The FDA approved atezolizumab and hyaluronidase-tqjs for all adult indications of intravenous atezolizumab. The U.S. Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as a subcutaneous injection to be offered...
The FDA approved lazertinib plus amivantamab-vmjw for the treatment of certain EGFR-mutated lung cancers. The U.S. Food and Drug Administration (FDA) has approved lazertinib (Lazcluze), in combination with amivantamab-vmjw (Rybrevant), for the first-line treatment...
Durvalumab can now be used with chemotherapy for certain patients with resectable non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted approval to the neoadjuvant combination of durvalumab (Imfinzi) and...
The FDA approved axatilimab-csfr, an inhibitor of monocytes and macrophages, for certain patients with chronic graft-versus-host disease. The U.S. Food and Drug Administration (FDA) has approved axatilimab-csfr (Niktimvo) for the treatment of adult and...
The FDA has approved vorasidenib to treat certain brain tumors harboring an IDH1 or IDH2 mutation. The U.S. Food and Drug Administration (FDA) has approved vorasidenib (Voranigo) for the treatment of adult and pediatric...
Afamitresgene autoleucel has received accelerated approval to treat certain patients with synovial sarcoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to afamitresgene autoleucel (Tecelra, afami-cel) for the treatment of certain...
The FDA has approved dostarlimab-gxly plus chemotherapy to treat more patients with endometrial cancer. The U.S. Food and Drug Administration (FDA) has approved dostarlimab-gxly (Jemperli) in combination with the chemotherapies carboplatin and paclitaxel, followed...
The targeted therapy was approved by the FDA for use in combination with bortezomib, lenalidomide, and dexamethasone. The U.S. Food and Drug Administration (FDA) has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro), plus bortezomib, lenalidomide,...
The FDA approved the immunotherapy epcoritamab-bysp for certain patients with follicular lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to epcoritamab-bysp (Epkinly) for the treatment of adult patients with follicular...
The FDA issued its first approval for the use of A KRAS G12C inhibitor in a tumor type other than lung. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to adagrasib...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now